Ipsen is pleased to announce a strong first-quarter total-sales performance. Total sales, excluding Consumer HealthCare, grew by 9.6% at constant exchange rates1, driven by our Oncology and Neuroscience medicines. We issued confirmation of our full-year guidance for 2022, with total-sales growth greater than 2.0% at CER1 and a core operating margin greater than 35.0% of total sales2.
In February, we announced that we had entered exclusive negotiations with Mayoly Spindler for the divestment of the Consumer HealthCare (CHC) business. This transaction is anticipated to be completed before the end of Q3 2022.
David Loew, Chief Executive Officer, commented: “The execution of our strategy was reflected in our first-quarter performance across the business. The strong sales were in line with our expectations, with key oncology assets delivering double-digit growth. Our guidance for the year is underpinned by our strong platform of growth across our core and innovative medicines.
We look forward to several important clinical trial data readouts in the second half, while our pipeline will continue to be replenished through the external-innovation strategy. It is an exciting time for Ipsen as we deliver on our strategy, produce strong results, expand our pipeline and focus together, for patients and society.”
You can find the press release here
1 At constant exchange rates (CER), which exclude any foreign-exchange impact by recalculating the performance for the relevant period by applying the exchange rates used for the prior period.
2 Total sales in this announcement are unaudited IFRS consolidated sales and reflect Specialty Care sales only, in accordance with IFRS 5.
